Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Operating Margin: 2014-2025

Historic Operating Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -56.70%.

  • Viridian Therapeutics, Inc.\DE's Operating Margin rose 9701307.00% to -56.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -463.52%, marking a year-over-year increase of 9325900.00%. This contributed to the annual value of -99,018.21% for FY2024, which is 1798318.00% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Operating Margin stood at -56.70%, which was up 99.96% from -142,356.00% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Operating Margin's 5-year high stood at -56.70% during Q3 2025, with a 5-year trough of -142,356.00% in Q2 2025.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Operating Margin averaged around -90,539.37%, with its median value being -97,069.77% (2024).
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by 7,077,795bps in 2023, then skyrocketed by 9,701,307bps in 2025.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Operating Margin stood at -13,589.25% in 2021, then crashed by 3,314,027bps to -46,729.52% in 2022, then plummeted by 5,254,548bps to -99,275.00% in 2023, then slumped by 2,221,389bps to -121,488.89% in 2024, then soared by 9,701,307bps to -56.70% in 2025.
  • Its last three reported values are -56.70% in Q3 2025, -142,356.00% for Q2 2025, and -130,369.44% during Q1 2025.